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BACKGROUND: There is mounting evidence that individuals with kidney disease and kidney stones have 
an abnormal gut microbiota composition. No studies to date have summarised the evidence to categorise 
how the gut microbiota profile of these individuals may differ from controls. Synthesis of this evidence is 
essential to inform future clinical trials. This systematic review aims to characterise differences of the gut 
microbial community in adults with kidney disease and kidney stones, as well as to describe the 
functional capacity of the gut microbiota and reporting of diet as a confounder in these studies. 
METHODS: Included studies were those that investigated the gut microbial community in adults with 
kidney disease or kidney stones and compared this to the profile of controls. Six scientific databases 
(CINHAL, Medline, PubMed, Scopus, Web of Science and Cochrane Library), as well as selected grey 
literature sources, were searched. Quality assessment was undertaken independently by three authors. 
The system of evidence level criteria was employed to quantitatively evaluate the alteration of microbiota 
by strictly considering the number, methodological quality and consistency of the findings. Additional 
findings relating to altered functions of the gut microbiota, dietary intakes and dietary methodologies 
used were qualitatively summarised. RESULTS: Twenty-five articles met the eligibility criteria and included 
data from a total of 892 adults with kidney disease or kidney stones and 1400 controls. Compared to 
controls, adults with kidney disease had increased abundances of several microbes including 
Enterobacteriaceae, Streptococcaceae, Streptococcus and decreased abundances of Prevotellaceae, 
Prevotella, Prevotella 9 and Roseburia among other taxa. Adults with kidney stones also had an altered 
microbial composition with variations to Bacteroides, Lachnospiraceae NK4A136 group, 
Ruminiclostridium 5 group, Dorea, Enterobacter, Christensenellaceae and its genus Christensenellaceae 
R7 group. Differences in the functional potential of the microbial community between controls and adults 
with kidney disease or kidney stones were also identified. Only three of the 25 articles presented dietary 
data, and of these studies, only two used a valid dietary assessment method. CONCLUSIONS: The gut 
microbiota profile of adults with kidney disease and kidney stones differs from controls. Future study 
designs should include adequate reporting of important confounders such as dietary intake to assist with 
interpretation of findings. 
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Abstract
Background: There is mounting evidence that individuals with kidney disease and kidney stones have an abnormal
gut microbiota composition. No studies to date have summarised the evidence to categorise how the gut
microbiota profile of these individuals may differ from controls. Synthesis of this evidence is essential to inform
future clinical trials. This systematic review aims to characterise differences of the gut microbial community in adults
with kidney disease and kidney stones, as well as to describe the functional capacity of the gut microbiota and
reporting of diet as a confounder in these studies.
Methods: Included studies were those that investigated the gut microbial community in adults with kidney disease
or kidney stones and compared this to the profile of controls. Six scientific databases (CINHAL, Medline, PubMed,
Scopus, Web of Science and Cochrane Library), as well as selected grey literature sources, were searched. Quality
assessment was undertaken independently by three authors. The system of evidence level criteria was employed to
quantitatively evaluate the alteration of microbiota by strictly considering the number, methodological quality and
consistency of the findings. Additional findings relating to altered functions of the gut microbiota, dietary intakes
and dietary methodologies used were qualitatively summarised.
Results: Twenty-five articles met the eligibility criteria and included data from a total of 892 adults with kidney
disease or kidney stones and 1400 controls. Compared to controls, adults with kidney disease had increased
abundances of several microbes including Enterobacteriaceae, Streptococcaceae, Streptococcus and decreased
abundances of Prevotellaceae, Prevotella, Prevotella 9 and Roseburia among other taxa. Adults with kidney stones also
had an altered microbial composition with variations to Bacteroides, Lachnospiraceae NK4A136 group,
Ruminiclostridium 5 group, Dorea, Enterobacter, Christensenellaceae and its genus Christensenellaceae R7 group.
Differences in the functional potential of the microbial community between controls and adults with kidney disease
or kidney stones were also identified. Only three of the 25 articles presented dietary data, and of these studies, only
two used a valid dietary assessment method.
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Conclusions: The gut microbiota profile of adults with kidney disease and kidney stones differs from controls.
Future study designs should include adequate reporting of important confounders such as dietary intake to assist
with interpretation of findings.
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Background
The link between the gut microbiome and human dis-
eases continues to emerge in recent literature and has
become a focus for global scientific endeavours to miti-
gate kidney disease development and progression [1].
The human microbiome is a complex ecosystem com-
prising of all the genetic material inside the trillions of
microorganisms that live within and on us. Whereas, the
microbiota is the community of micro-organisms found
in a particular sample or location, which includes bac-
teria, bacteriophage, viruses, fungi, and protozoa [2, 3].
Advancements in microbial characterisation methods
have facilitated our understanding of the complex mech-
anistic links between the microbiome and disease. There
are numerous methods to categorise gut microbial com-
position and measure diversity. For instance, some
methods are based on sequence divergences of the small
subunit ribosomal RNA (16S rRNA) [4, 5], which pro-
vide helpful insights into the diversity of the gut micro-
biota, as well as qualitative and quantitative information
based on what microbes are present. Examples of this
technique include fluorescence in situ hybridization
(FISH), DNA microarrays, and next-generation sequen-
cing of the 16S rRNA gene or its amplicons [5]. Metage-
nomic or shotgun sequencing is another type of analysis
which randomly sequences all extracted DNA in a given
sample. This technique offers a higher taxonomic reso-
lution by allowing the identification of microbial taxa
present in a community at the species and strain level,
in addition to providing information on the functional
potential of the microbial community [4–6].
The microbiota encompasses far more metabolic genes
than that of the human genome [2] and offers humans
with additional unique functional capabilities via specific
enzymes and metabolic pathways. Typically, these mi-
crobes have a harmonious relationship with their host
[7] and contribute to several functional activities includ-
ing micronutrient and immune homeostasis, energy me-
tabolism, and host defences against pathogens [2, 8, 9].
However, in individuals with chronic kidney disease
(CKD), evidence suggests that a microbial imbalance
(dysbiosis) leads to an increase in harmful nephrovascu-
lar uraemic toxins [10–13]. The retention of these ur-
aemic toxins, particularly indoxyl sulphate (IS), p-Cresyl
sulphate (pCS), phenylacetylglutamine (PAG) and tri-
methylamine N-oxide (TMAO) have been associated
with adverse complications, all of which negatively im-
pact on the quality of life for individuals living with kidney
disease. These complications include accelerated disease
progression [14, 15], increased risk of cardiovascular-
related mortality [15–17] and common symptoms such as
constipation and cognitive decline [18]. Currently, the
only known mechanism for reducing uraemic toxins in
CKD is dialysis. Nevertheless, existing evidence indicates
that only the free fraction of the protein-bound toxins
pCS and IS can diffuse across the dialysis membrane,
resulting in a limited capacity for removal [11]. Therefore,
the development of novel strategies (other than dialysis)
to reduce the production of major uraemic toxins, particu-
larly in the earlier stages of CKD, is warranted.
The role of the gut microbiota in kidney stone disease
historically focused on the presence of Oxalobacter for-
migeme [19], a gram-negative bacterium with the func-
tional ability to degrade oxalate. Thus, a deficiency of
Oxalobacter formigene present in stool samples was pre-
viously assumed to be a risk factor for kidney stone dis-
ease [20–22]. However, clinical studies provided
questionable results, as Oxalobacter formigene has also
been isolated from samples of recurrent stone formers
[23, 24]. Since advancements in culture-independent
methods for gut microbiota investigations that have be-
come more available in the last decade [5], studies have
made attempts to evaluate the relationship between gut
microbiota and kidney stone formation in more compre-
hensive ways, shedding new light on the gut-kidney axis
in nephrolithiasis.
Diet forms a critical component in the overall medical
strategy for kidney disease and plays a fundamental role
in determining the composition and functional activity
of the human gut microbiota [25], with implications for
uraemic toxin production [11, 13, 26–28]. Moreover,
diet-based approaches such as ensuring adequate intake
of fluid and dietary calcium, while avoiding high intakes
of sodium and animal protein are crucial non-
pharmacological prevention strategies for kidney stone
disease. Therefore, dietary interventions and targeted
nutritional therapies offer a potential approach to
microbiota-associated diseases and mitigate uraemic
toxin generation and kidney stone formation. Investiga-
tions into how the gut microbiota differs with disease
and lifestyle factors such as diet will enhance not only
our understandings of the contribution these microbes
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have in host biology but also understandings of the com-
plicated exchange between diet and disease.
Differences in the composition of the gut microbiota
in kidney disease and kidney stone populations com-
pared to controls remains unclear due to the lack of a
quantitative overview of existing evidence. The investiga-
tion into how the microbial signatures of adults with
kidney disease or kidney stones may deviate from controls
is essential to inform future trials. Hence, this review aims
to systematically characterise the gut microbial compos-
ition in adults with kidney disease or kidney stones com-
pared to controls and gain a better understanding of the
functional capacity of the microbiota and reporting of diet
as a confounder in these studies.
Methods
Protocol
The systematic literature review was reported following
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [29] and registered at
PROSPERO (No. CRD42018109173, http://www.crd.york.
ac.uk/).
Article selection
The inclusion criteria were as follows:
(1) Original research that examined the gut microbial
community from adults with kidney disease or
kidney stones and compared that to controls. This
encompassed studies which reported to include
adults with CKD; end-stage kidney disease (ESKD);
glomerulonephritis; nephrotic syndrome; IgA
nephropathy (IgAN); polycystic kidney disease;
diabetic nephropathy (DN); Alport syndrome; Fabry
disease; individuals who are receiving renal
replacement therapies such as haemodialysis
(HD), peritoneal dialysis (PD), kidney transplant
(KT); or adults with kidney stones (any stone
type).
(2) Studies reporting on the microbial community from
stool or intestinal biopsy samples;
(3) Full-text articles available in English.
Studies for exclusion were:
(1) Animal or in-vitro studies, case reports, abstracts,
commentaries, review articles, editorials, expert
opinion, letters, guidelines, protocols, seminars,
reports, books or book chapters;
(2) Study populations which included children;
(3) Study populations which included adults with acute
conditions (haemolytic uremic syndrome, acute
kidney injury or urinary tract infections), renal
cancer, kidney-yin deficiency syndrome or stones
which were reported in other sites, such as the ur-
eter or urethra.
Search strategy and study selection
Six scientific databases including CINHAL, Medline,
PubMed, Scopus, Web of Science and Cochrane Library
as well as grey literature sources: Trove, the National Kid-
ney Foundation Website, Google Scholar, Google.com.au,
National Institute for Clinical Excellence (NICE) and TRIP
Medical Database, were searched up until 7th August
2018. A research librarian was consulted to refine search
terms and selection of databases. Reference lists of manu-
scripts were also scanned to discover additional relevant
articles. A full-updated search using the original search
strategy was undertaken on the 3rd October 2019 using
the same six scientific databases as well as Google Scholar.
The search strategy for all databases can be found in Item
1 of this manuscript’s supplementary information (Add-
itional file 1). All citations were imported by one member
of the research team in Endnote (Endnote X8, Thomson
Reuters, 2016) for review.
Two reviewers [JS, RI] independently screened the titles,
abstracts and full texts for inclusion in this review. Dis-
crepancies were resolved by consensus or adjudication by
other members of the research team [KC, KL]. At the
stage of full-text review, the decision to restrict articles to
only those that included at least one of the following
methods was made: Metagenomic sequencing (shotgun
sequencing), amplicon-based sequencing methods includ-
ing 16S rRNA sequencing, quantitative real-time polymer-
ase chain reaction (qPCR) sequencing, DNA microarray
or fluorescence in situ hybridization (FISH) techniques.
These methods are culture-independent methods that en-
able phylogenetic identification and quantification, which
will help to provide novel insights into the composition
and/or diversity of the microbiota.
Summary measures
The overall microbiota structure (α-diversity and β-
diversity) and differences in the abundance of microbes
at specific taxonomic levels (phylum, order, class, family,
genus, species, OTU) were the primary outcomes of this
paper. The secondary outcomes were descriptions of the
real or predicted functional capacity of the microbiota,
details on dietary intake and the dietary assessment
methods used in each study.
Data extraction and quality assessment
Relevant data in all eligible studies were extracted into
an excel spreadsheet by one investigator, and another
member of the research team cross-checked 25% of the
input. Only statistically significant results (p < 0.05) that
reported compositional differences of the gut microbiota
between the groups of interest compared to controls, at
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each taxonomic level, were imported into excel. Add-
itional information was also extracted: country of study,
demographics (age, gender, and ethnicity), sample col-
lection and storage methods, description of antibiotic
and medication use, type of taxonomic database used,
microbial characterisation method, microbial diversity
metrics, and dietary methods.
To assess the quality of studies, three independent re-
viewers [JS, KL, ASN] used the Newcastle-Ottawa Scale
(NOS) [30]. Appraisal items in the NOS tool were
grouped into three categories: the selection of the study
groups; the comparability of the groups; and the ascer-
tainment of the exposure (the collection and assessment
of samples for microbial communities) as the outcome
of interest [30]. Overall, studies which scored seven or
above using the NOS tool was considered to be of ‘high-
quality’ [30–32].
Data synthesis
Due to the heterogeneity of study methods and the ab-
sence of raw sequencing data, it was not possible to under-
take a meta-analysis. Instead, a quantitative assessment of
the microbial composition was performed. The quantita-
tive approach applied the system of evidence level criteria
(Table 1), according to a ranking-based system docu-
mented elsewhere [33–35]. Benefits of this approach are
that it considers the number and methodological quality of
included studies, as well as the consistency of reported
findings. Study findings were deemed highly consistent
and graded as ‘strong evidence’ when 75% or more of the
studies that reported a particular bacteria were in agree-
ment, whereby the same trend in microbial alteration (in-
creased or decreased) relative to controls was found in at
least two high-quality studies as determined by the NOS
quality score. Finally, data on the functional potential of the
microbial community, dietary intakes and dietary assess-
ment methodologies used were qualitatively summarised.
Results
Summary of included studies
The original literature search yielded 4155 articles, of
which 110 full-text articles were evaluated. The updated
search provided an additional 1388 papers, of which nine
full-text articles were suitable for inclusion. A total of 25
articles met the eligibility criteria (Fig. 1). All 25 papers
reported cross-sectional data on 722 adults with kid-
ney disease, 170 adults with kidney stones and 1400
control participants (Table 2). Only different results
obtained from the papers using the same study popula-
tions [36–38, 48] were extracted to avoid duplication.
Majority of articles reported on adults with CKD who
were not receiving a renal replacement therapy, includ-
ing studies that exclusively investigated IgAN [39] and
DN cohorts [40, 41] (Table 2, n = 10). Three papers in-
vestigated adults undertaking HD, and another study in-
cluded individuals receiving PD therapy. Five additional
articles included mixed kidney disease cohorts within
their sample. No studies reported to exclusively investi-
gate the gut microbiota profile in individuals with glom-
erulonephritis, nephrotic syndrome, polycystic kidney
disease, Alport syndrome, Fabry disease, and compared
that to a control group. The remaining six articles inves-
tigated adults with kidney stones. The age structure of
cohorts did vary; although there was some overlap across
studies, including a mean sample population age be-
tween 41 and 64.5 years. The portion of males ranged
from 22 to 100%. Overall, studies were predominately
from China (n = 12/25), followed by the United States of
America (n = 3/25) and Italy (n = 2/25).
All eligible studies used stools samples for their gut
microbiota analysis. Eighteen articles reported using fro-
zen stool samples for their analysis, where storage temper-
atures ranged from − 20 °C to − 80 °C. Others reported
that samples were processed within 24 h of receipt [42] or
kept on ice and processed within 1 h of defecation [43].
The remaining articles failed to provide sufficient details
regarding the storage and processing methods utilised [36,
44–46, 48]. Four articles assessed the gut microbiota using
only qPCR [41, 43, 47, 49]. The remaining studies assessed
gut microbiota via high-throughput molecular approaches:
Illumina platforms (MiSeq, NextSeq, HiSeq), Iron Torrent
PGM system or bTEFAP using 454 FLX sequencer, DNA
microarray analysis performed using PhyloChip assay.
However, three papers did not report the sequencing plat-
form used [44, 45, 55]. Among these studies, four
employed a combination of microbial characterisation
techniques in addition to 16S rRNA sequencing, includ-
ing: shotgun sequencing [50]; qPCR [38, 37, 51]; denatur-
ing gradient gel electrophoresis (DGGE) fingerprinting
[38] as well as gene-targeted amplicon sequencing of func-
tional genes involved in oxalate and butyrate metabolism
(frc- [37, 38], but- and buk- gene [37]). Two research
groups also utilised fungal specific primers for their qPCR
analysis [41], as well as 18S rRNA and fungal ITS1 region
primers for amplicon sequencing [37] to explore members
of the microbial communities other than just bacteria.
Table 1 The system of evidence level criteria
Grading Criteria
Strong Consistent findings (≥75%) in at least 2
high-quality studies
Moderate Consistent findings (≥75%) in one high-quality
study and at least one low-quality study
Weak Findings of one high-quality study or consistent
findings (≥75%) in at least 3 or more low-quality
studies
Inconclusive Inconsistent findings, or consistent findings
(≥75%) reported in less than 3 low-quality studies
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Risk of bias and heterogeneity
Using the Newcastle-Ottawa Scale, of the 25 final arti-
cles, 11 were considered high-quality with a score of
seven or above (Table 3). There were multiple sources of
heterogeneity among studies, including: the collection,
handling and storage temperature of samples, DNA ex-
traction method, the primer used for PCR, the variable
region of the conserved genes (for instance the 16S
rRNA gene) and the sequencing platform used. Also,
some methods employed cannot evaluate the whole mi-
crobial community, such as qPCR, which can only detect
selected microbes. Moreover, although there were some
consistencies, many papers differed with their statisti-
cally analysis and presentation of the gut microbial data.
A few articles were also not consistent in reporting the
CKD stage of their participants or details of the diagnostic
criteria used for the classification of CKD. Other sources
of heterogeneity included the age, gender, ethnicity
of participants and the recruitment of controls. For in-
stance, one study only recruited males [38], while seven of
the eight papers that reported ethnicity recruited one eth-
nic group: Chinese [40, 47, 51–53, 56] or Caucasian [39].
Details relating to the recruitment of control groups were
often missing or differed across studies, with some articles
reporting that their controls were hospital or clinic staff.
Furthermore, the classification of ‘controls’, the timing of
antibiotic usage before study participation, reporting of
medications and other co-existing conditions was not con-
sistent across studies and more often poorly defined.
Microbial diversity and richness
Alpha (α) diversity is the measure of the number (richness)
and distribution (evenness) of taxa within a sample [54].
Sixteen articles reported results for α-diversity, of which five
observed no significant difference between groups [38, 45,
48, 51, 53]. Eight articles reported that α-diversity was
Fig. 1 PRISMA flow diagram
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significantly reduced in adults with kidney disease or kidney
stones relative to controls, among which seven papers re-
ported a statistically signficant p-value [39, 46, 50, 52, 56,
57, 62]. Interestingly, the remaining three studies observed
a significant increase in α-diversity (observed species/
OTUs) in individuals with ESKD, DN and those undergo-
ing HD therapy compared to controls [40, 44, 55].
Beta (β) diversity, a measure of the diversity that repre-
sents the similarity or difference in microbial composition
between sites or different samples [54], was evaluated in
12 studies (using Bray-Curtis, weighted and unweighted
UniFrac distance metrics). Ten studies reported compos-
itional differences in the overall microbial communities
between controls and kidney disease or kidney stone co-
horts, of which six studies [40, 46, 50, 52, 56, 57] reported
a statistically significant p-value (Table 2).
Altered microbial composition
Alterations of the microbial composition were presented
into two larger groups: adults with kidney disease and adults
with kidney stones. To highlight alterations of the microbial
composition specific to individuals receiving dialysis treat-
ment, data from relevant articles that included adults under-
taking HD or PD therapy are presented as a sub-analysis.
Microbiota profile of adults with kidney disease compared
to controls
Figure 2 characterises the differences in the gut microbiota
profile of individuals with kidney disease compared to con-
trols. Based on strong level of evidence criteria, 20 micro-
bial taxa were reported as being differentially abundant. For
instance, adults with kidney disease had relatively increased
abundances of Proteobacteria, Enterobacteriaceae, Strepto-
coccaceae, Streptococcus and decreased abundances of
Firmicutes, Prevotellaceae, Prevotella, and Prevotella 9.
Based on the moderate evidence criteria, nine other taxa
were less abundant in comparison to controls including
Alcaligenaceae, Roseburia, Faecalibacterium and Faecali-
bacterium prausnitzii. In contrast, Bilophila, Desulfovibrio,
Klebsiella, Escherichia-Shigella, along with four other taxa
were more highly abundant (Fig. 2).
The population of an additional 112 microbial taxa
were altered, but this was based on weak evidence (data
not shown; Table S1, Additional file 1). Of these, 53 taxa
were more abundant in individuals with kidney disease,
while the remaining 59 were less abundant when com-
pared to controls.
Microbiota profile of adults receiving dialysis therapy
Data from the six articles included in this sub-analysis
identified that five microbial taxa including Alphapro-
teobacteria, Streptococcaceae, and Streptococcus were
more abundant in adults receiving dialysis than controls
based on strong evidence criteria (Fig. 3). Based on mod-
erate evidence criteria, the abundance of Bacteroidetes
was reduced, while Enterobacteriaceae was higher in
adults undergoing dialysis therapy. Results from two
other studies [46, 60] were not included in this sub-
analysis because it was unclear if the CKD cohort were
receiving haemodialysis at the time of sample collection
[46], and whether the results of individuals undertaking
dialysis therapy were statistically significant compared to
controls [60].
Stadlbauer et al. [57] investigated differences in the mi-
crobial profile according to dialysis type. Compared to
controls, adults receiving PD had reduced abundances of
Comamonadaceae and Campylobacteraceae and in-
creased abundances of Ruminococcaceae and Corpococcus.
In HD participants, microbial families Comamonadaceae
and Campylobacteraceae were reportedly enriched, while
Table 3 Quality assessment of included articles (n = 25)
Reference Sampling (4 points) Confounders controlled (2 points) Exposure (3 points) Total rating (9 points)
[37] – − − − – − + + − 2
[60] – − − − + − + + − 3
[44, 46] + − − − – − + + + 4
[41] – − − − + − + + + 4
[36, 48] + − − − + − + + + 5
[55] + + − − – − + + + 5
[45] + − − + – − + + + 5
[38, 39, 47, 51] + − − − + + + + + 6
[42] + + − − + − + + + 6
[43, 53, 56, 57, 58, 61] + + − − + + + + + 7
[40, 49, 52, 62] + − − + + + + + + 7
[50] + + + − + + + + + 8
Legend: ‘+’ Quality criterion satisfied; ‘-’ Quality criterion not satisfied or insufficient information to adjudicate as satisfied. Studies with a quality score of seven or
above were considered high-quality
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Fig. 3 Sub-sample analysis of altered taxa based on strong and moderate level of evidence for adults with kidney disease receiving dialysis
therapy compared to controls. Figure includes data only from the studies that investigated adults receiving HD or PD therapy
Fig. 2 Altered taxa based on strong and moderate level of evidence for adults with kidney disease compared to controls. Figure includes data
from studies that investigated adults with CKD, IgAN, DN, ESKD, KT recipients and individuals receiving dialysis therapy (HD and PD)
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Faecalibacterium prausnitzii, Roseburia intestinalis and
Clostridium nexile were depleted compared to controls.
Microbiota profile of kidney transplant recipients
One study in this review [46] included a sub-set of adults
who received a KT (n = 16) within the prior month of
study commencement. Their findings revealed that 54
taxa were altered compared to controls: Firmicutes, Faeca-
libacterium, Prevotella and three other bacterial members
were less abundance, while Bacteroidetes, Proteobacteria,
Alphaproteobacteria, Streptococcaceae, Streptococcus
along with 43 other taxa were enriched in individuals who
received a KT (data not shown; Table S1, Additional file 1).
Authors reported that based on the abundance of major
phyla, the overall gut microbial structure of KT recipients
was more similar to the participants with CKD (stages 3–4)
rather than the controls [46]. However, several microbial
taxa were unique to KT recipients. For example, Proteobac-
teria and Enterobacteriaceae were more highly abundant in
KT recipients in comparison to the CKD cohort.
Microbiota profile of adults with kidney stones compared to
controls
Based on strong evidence criteria, seven taxa were ob-
served to be altered in adults with kidney stones. Within
the phylum Firmicutes, Lachnospiraceae NK4A136 group,
Ruminiclostridium 5 group, Dorea, Christensenellaceae, its
genus Christensenellaceae R7 group, as well as Enterobac-
ter (from the Proteobacteria phylum) were all significantly
reduced compared to controls (Fig. 4). In contrast, Bacter-
oides was more highly abundant in adults with kidney
stones. Finally, the abundance of two other taxa, Bifido-
bacterium and Faecalibacterium were found to be signifi-
cantly reduced based on moderate evidence criteria in
adults with kidney stones (Fig. 4).
The population of an additional 85 microbial taxa
were altered in kidney stone populations compared
to controls, but this was based on weak evidence
(data not shown; Table S2, Additional file 1), of
which 32 microbes increased and 53 taxa decreased.
Presence and absence data of archaea, microeukar-
yotes and fungi from Survyanshi et al. [37] were not
included as it was unclear if results were statistically
significant. Given this was the only paper that
employed a high-throughput approach to examine
different microbial community members (other than
bacteria), it seemed relevant to summarise their find-
ings in the manuscript's supplementary information
(Table S3, Additional file 1).
Microbial markers for the potential detection of kidney
disease and kidney stones
Six studies reported values of the area under the receiver
operating characteristic (ROC) curve (AUC), ranging
between 0 and 1 [59]. The higher AUC value, the better
the test or model is at distinguishing between partici-
pants with disease and no disease [59]. Findings amongst
these studies were inconclusive.
Li et al. [52] identified Akkermansia (AUC = 0.753) and
Lactobacillus (AUC = 0.792) was able to differentiate be-
tween adults with CKD and controls, while the combin-
ation of both genera achieved the best result (AUC=
0.830). Lun et al. [60] reported that Lachnospira (AUC =
0.813) performed best for controls, while Ruminococcus
gnavus (AUC = 0.764) was best to detect adults with CKD.
In another study [46], the presence of 4 genera from the
bacterial family Lachnospiraceae (Shuttleworthia, Pseudo-
butyrivibrio, Roseburia and Lachnospira) were able to
identify adults with CKD from controls with high accuracy
(AUC= 0.92). The model by Tao et al. [40], which in-
cluded Escherichia Shigella and Prevotella 9, had an
Fig. 4 Altered taxa based on strong and moderate level of evidence for adults with kidney stones compared to controls
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AUC= 0.86 for predicting DN in their study population.
In adults with kidney stones, Tavasoli et al. [49] reported
that none of the bacteria examined in their study was able
to generate an acceptable AUC to differentiate from con-
trols, while Tang et al. [53] reported that Pseudomonas
aeruginosa and Escherichia coli could be used to classify
their nephrolithiasis patients accurately (AUC = 0.947 and
AUC = 0.840, respectively).
Altered genetic functions of the microbiota
Among nine studies, eight [37, 38, 40, 46, 50, 52, 56, 57]
reported that the real or predicted functional capacity of
the gut microbiota in adults with kidney disease and kid-
ney stones were substantially different from controls. Only
one of these study [50] undertook shotgun sequencing in
a subset of their study population (n = 10 participants) to
investigate the real functional potential of the microbial
communities for known metabolic pathways. Functional
gene-targeted amplicon sequencing was also employed by
another research group [37, 38]. However, the majority of
studies predicted the functional capacity of the gut micro-
biota using the bioinformatic software platform PICRUSt
(Phylogenetic Investigation of Communities by Recon-
struction of Unobserved States) [38, 40, 46, 52, 53, 56, 57].
In adults with stage 4–5 CKD, using PICRUSt, functional
genes relating to trimethylamine (TMA) metabolism were
increased (K07811, K07821, and K03532), while functional
genes relevant to choline, betaine and L-carnitine metabol-
ism (K07271, K01004, K00499, K00130 and K00540) were
found to be significantly reduced compared to controls
[56]. In another study investigating adults with CKD, mi-
crobial genes associated with the circulatory system func-
tion were predicted to be significantly enriched, while
polyketide metabolism, as well as cell motility and secre-
tion, was reduced relative to controls [52]. Similarly, Guir-
ong et al. [46] also found that predicted microbial genes
relevant to polyketides metabolism were also significantly
reduced in adults with CKD and KT recipients along with
genetic information processing (involving the ribosome,
homologous recombination, and aminoacyl-tRNA), metab-
olism of co-factors, vitamins, nucleotides, terpenoids and
cellular processes including pyrimidine metabolism. Com-
pared to controls, KT recipients and adults with CKD had
significantly greater predicted microbial genes associated
with the metabolism of carbohydrates, other amino acids,
and xenobiotics [46]. Differentially abundant bacterial func-
tions related to lipid metabolism were reported between
DN, T2DM controls and controls [40]. In adults undergo-
ing dialysis (HD or PD), four functional pathways relevant
to the renin-angiotensin system, glycosphingolipid biosyn-
thesis, isoflavonoid biosynthesis and vasopressin regulated
water reabsorption were different compared to controls
[57]. However, the authors [57] did not report if these
functional pathways were upregulated or downregulated.
In adults with kidney stones, shotgun sequencing ana-
lysis found that functional genes involved in oxalate deg-
radation, such as formyl-CoA transferase and oxalyl-CoA
decarboxylase, were significantly reduced compared to
controls [50]. The highest representation of these genes
was detected in some Archaea and Bacteria, either with
known (Oxalobacter formigenes) or previously unknown
oxalate-degrading properties (Escherichia coli, Eggerthella
spp., Roseburia hominis, Bacteroides massiliensis, Clostrid-
ium citroniae) [50]. Through the application of DGGE fin-
gerprinting and targeted-gene sequencing of the frc-gene,
Suryavanshi et al. [38] also confirmed that in addition to
Oxalobacter formigenes, several gut inhabitants possessed
the ability to metabolise oxalate. However, Suryavanshi
et al. [38] findings using PICRUSt completely contrasted
the shotgun sequencing results [50], as several genes in-
volved in oxalate degradation were reported to be
enriched rather than depleted in their kidney stone cohort
[38]: formate dehydrogenase (K08349), oxalate/formate
antiporter (K08177), formyl-CoA transferase (K07749),
oxalyl-CoA decarboxylase (K01577) and oxalate decarb-
oxylase (K01569). Tang et al. [53], who also investigated
these same metabolic pathways relevant to oxalate degrad-
ation, reported observing no significant difference between
groups. Other predicted functional activities of the gut
microbiota relating to energy metabolism, glycan synthe-
sis, metabolism of co-factors and vitamins were down-
regulated, while lipid metabolism, carbohydrate metabol-
ism and xenobiotic degradation metabolism were upregu-
lated in adults with kidney stones [38]. In more recent
work [37], through targeted-gene sequencing of the buk-
gene, numerous butyrate-producing bacterial species that
were present in controls, were not found in samples from
participants with kidney stones.
Wong et al. [36] employed a different approach to the
above methods. This research group adopted a targeted
approach using the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database as well as a literature review
to search for corresponding functional genes of interest
alongside the list of bacterial families that differed in
relative abundance between adults receiving HD and
controls [36]. In individuals undertaking HD therapy, 12
of the 19 microbial families that were of highest abun-
dance were urease-possessing families, while an add-
itional five families reportedly possessed the uricase gene
(Cellulomonadaceae, Dermabacteraceaea, Micrococca-
ceae, Polyangiaceae, Xanthomonadaceae). Three bacter-
ial families were believed to contain the tryptophanase
gene (Clostridiaceae, Enterobacteriaceae, and Verruco-
microbiaceae) and four were suspected to be capable of
deaminating tyrosine into p-Cresol, a precursor of pCS.
Furthermore, two of three bacterial families (Lactobacil-
laceae and Prevotellaceae) that were less abundant in
adults receiving HD have reported butyrate-producing
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functions, including members that possess phospho-
transbutyrylase and butyrate kinase genes.
Dietary intake assessment and methodologies
Three of the 25 articles (12%) presented dietary intake re-
sults, of which two considered diet in their analysis [50, 61].
The authors concluded that dietary factors did not seem to
be involved in kidney disease− or nephrolithiasis−associ-
ated abnormalities of the gut microbial composition.
Of the three papers, two used the 131-item European
Prospective Investigation of Cancer and Nutrition (EPIC)
Food Frequency Questionnaire (FFQ) [50, 61], one of which
employed a trained research nutritionist to administer the
FFQ [50]. Barrios et al. [61] generated dietary scores from
the FFQ results through principal component analysis [61].
These dietary scores were then considered as covariates in
their analysis of the gut microbiota. In the second study,
Ticinesi et al. [50] assessed total energy (kcal), macronutri-
ent (protein, carbohydrates, fats in grams), dietary fibre
(grams), alcohol (grams) and micronutrient consumption
(grams) between groups (adults with kidney stones and
controls). Only dietary calcium intake, along with other out-
comes such as BMI, age, the sex were adjusted as covariates
in microbiota analyses [50]. The third study presented
macronutrient percentage consumption of total energy in-
takes for carbohydrates, proteins and fats between groups,
but details relaying the methods used for data collection, or
if the dietary data were considered in the analysis, were
missing [42]. Other papers included in this review did not
present results or assess actual dietary intakes. For instance,
authors simply reported that their cohort groups had simi-
lar eating habits [40, 62], or noted which participants were
self-reported vegetarians [38]. Other articles stated their
participants had received dietary restrictions without detail-
ing the specific nutrition prescription, nor the counselling
and compliance approaches used [48].
Discussion
To the best of our knowledge, this is the first systematic re-
view to quantitatively summarise the composition of the
gut microbiota profile in adults with kidney disease or kid-
ney stones compared to controls. There is consistent evi-
dence that the gut microbial composition is altered in
specific ways in adults with kidney disease and kidney
stones. However, more research in this area is required to
establish the specific role that these microbes have in kid-
ney disease physiology and importantly, the clinical rele-
vance in disease management. To further elucidate this,
studies should employ more sophisticated microbial char-
acterisation techniques appropriate for functional annota-
tion (for instance shotgun sequencing) with the integration
of other multi-omic technology such as metabolomics, as
well as investigate the gut microbiota in larger sample sizes
and different kidney disease populations. The findings from
this review also highlighted a significant gap in the current
evidence-base regarding a lack of reporting to control for
the potential confounding effects of dietary intakes.
Lower bacterial diversity has been observed in a range of
other clinical conditions, including inflammatory bowel
disease (IBD), obesity, type 1 and 2 diabetes and coeliac
disease [63, 64]. However, differences in the diversity of mi-
crobial communities between cohorts with kidney disease
and kidney stones compared to controls remained incon-
clusive in this review. The overall dissimilarity in the mi-
crobial community structure as evaluated via β-diversity
distance metrics was statistically significant in six studies.
However, conflicting results were found for α-diversity
measures. Seven studies provided evidence that α-diversity
significantly reduced in adults with kidney disease or kid-
ney stones relative to controls. In contrast, three studies re-
ported an increase in microbial richness in adults with
CKD, two of which investigated adults with ESKD [44, 55],
including those receiving haemodialysis therapy [55]. It
was inferred that the increase of microbial richness might
reflect the proliferation of certain bacterial species [44, 55].
The overgrowth of microbes with pathogenic potential
(pathobiont) has been observed along with increases in in-
testinal concentrations of uraemic toxins [65] associated
with the progression of kidney disease, leading to the loss
and breach in the intestinal epithelial barrier [65]. Dialysis
is believed to worsen this epithelial barrier injury caused by
CKD [66], partly due to intra-dialysis or post-dialysis
hypotension bowel ischemia, and bowel oedema attribut-
able to intra-dialysis fluid retention. Shi et al. [55] detected
bacterial DNA in plasma samples of 27% of participants
undergoing haemodialysis and 20% of their pre-dialysis
CKD subjects. Interestingly, most of the bacterial DNA
found in ESRD patients' blood was also found in their stool
samples, but not in the dialysate solutions [55]. The re-
searchers proposed that the bloodstream bacteria was pri-
marily derived from the dysbiotic intestinal microbiota,
and that HD exacerbates micro-inflammation in these pa-
tients to some degree by encouraging intestinal microbiota
translocation due to an impaired intestinal barrier [55].
Changes at the phylum level with the elevation of Pro-
teobacteria and decrease of Firmicutes was found in kid-
ney disease cohorts. Previous studies have reported this
enrichment of Proteobacteria is indicative of an unstable
microbial structure [67] and has been correlated to dis-
eases of inflammatory phenotype [67] such as cardiovas-
cular disease and IBD [68]. Lipopolysaccharides (LPS)
constitute the outer membranes of most Gram-negative
bacteria [69], and bacterial members of Proteobacteria
have been reported as potent LPS producers [70]. A con-
nection between low-grade inflammation, sustained by
LPS, and the development of metabolic disorders is well
established, including evidence that indicates subclinical
endotoxemia is a potential cause for inflammation in
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individuals with CKD [65]. A mechanistic exploration in
male C57BL/6 mice showed that endotoxemia resulted in
the activation of mTOR signalling in macrophages, lead-
ing to progressive kidney inflammatory injuries and subse-
quent fibrosis [71]. Several other taxa that were reportedly
altered in adults with kidney disease have been linked to
various clinical outcomes. For instance, Streptococcus,
along with Klebsiella that was more abundant in kidney
disease populations, has been positively associated with
serum uraemic toxin TMAO levels [42]. Similarly, Strepto-
coccus and Blautia were found to be related to other ur-
aemic toxins such as IS and pCS and inversely associated
with kidney function (eGFR) [62]. On the other hand,
known commensal bacteria [9, 72] such Prevotella, Rose-
buria [51] and Fecalibacterium prausnitzii [47] that were
depleted among kidney disease populations, were associ-
ated with a better kidney function (eGFR) [47, 51] and de-
creases in Cystatin C levels [51]. Similarly, Prevotella,
Prevotella 2, Prevotella 9 and Megamonas were also asso-
ciated with lower serum levels of IS and pCS [62], blood
urea nitrogen (BUN) and creatinine [46, 62].
Findings related to the predicted biological func-
tions of the microbial community in adults with kid-
ney disease supports the notion that the gut
microbiome may play an essential role in the produc-
tion of ammonia from urea, and formation of uraemic
toxin TMAO via the reduced decomposition of its
precursor TMA. Genes relevant to choline, betaine,
and L-carnitine metabolism were found to be down-
regulated [56], possibly resulting in the production of
redundant TMA in the intestinal tract. In addition,
the predicted expression of genes related to trimethy-
lamine (TMA) metabolism were increased in adults
with CKD [56]. Moreover, the majority of microbial
families that were enriched in a cohort of participants
receiving HD possessed the urease gene, while other
highly abundant microbial families possessed the uri-
case gene, tryptophanase gene and p-cresol forming
enzymes [36]. A reduction in bacterial families that
possess the butyrate-kinase gene and phosphotransbu-
tyrylase needed to produce butyrate, a four-carbon
SCFA [36] was also identified among adults receiving
HD therapy. The capacity to produce SCFAs is crit-
ical physiologically as they are needed to provide the
energy for the growth and proliferation of colonocytes
[73]; protection of the colonic epithelium from
damage by reactive oxygen species and immune-
modulating prostaglandins [73]; and aid in processes
that reduce luminal pH associated with the inhibition
of pathogenic microorganisms [74]. Interestingly, mi-
crobial genes essential to polyketide metabolism were
also predicted to be significantly reduced in adults
with CKD. Polyketides are a functionally diverse
family of bioactive natural products and have many
important uses for human health [75, 76]. For ex-
ample, polyketides that are widely used include anti-
bacterials (erythromycin), antifungals (amphotericin),
anti-cancer agents (doxorubicin), immunosuppressants
(rapamycin) and cholesterol-lowering agents [76].
Adults with kidney stones also had a unique gut micro-
biota profile compared to controls. For instance, Bacter-
oides were consistently reported to be in increased
abundance, while Dorea, Enterobacter, Christensenella-
ceae, and its genus Christensenellaceae R7 group, de-
creased in adults with kidney stones. Discrepancies existed
across studies concerning the up-regulation or down-
regulation of microbial genes involved in oxalate degrad-
ation. Although in a small sample of kidney stone partici-
pants, shotgun sequencing analysis did indicate that the
expression of genes involved in oxalate degradation were
significantly reduced [50]. However, findings across in-
cluded studies did agree that several microbes possessed
functional oxalate-degrading properties, challenging the
concept that the gut-nephrolithiasis-axis is merely limited
to Oxalobacter formigenes [38, 50]. Other predicted func-
tional activities of the gut microbiota involved in energy
metabolism, glycan synthesis, lipid and carbohydrate me-
tabolism were also altered compared to controls [38].
It is important to remark that predicting functional pro-
files through amplicon-based metagenomics (i.e. 16S
rRNA sequencing), which was the most common ap-
proach employed by studies, offers only a limited reso-
lution of the microbial communities’ functional potential
and does not substitute shotgun sequencing [4]. However,
the findings of both kidney disease and kidney stone pop-
ulations uncovered through amplicon-based metage-
nomics do provide valuable functional insights for future
research to undertake more in-depth explorations through
shotgun metagenomics, metatranscriptomics and meta-
proteomics needed to further our understandings.
Overall, the application of other multi-omic technolo-
gies in gut microbiota-related investigations of adults with
kidney disease or kidney stones was uncommon among
the included studies. Although, some research groups did
report results of their metabolomic analyses [39, 42, 56,
61, 62], a technique that involves identifying a set of me-
tabolites within a sample [77]. For instance, De Angelis
et al. [39] observed differences in faecal and urinary me-
tabolome composition between IgAN patients and con-
trols. The authors suggested that elevated serum-free
amino acids detected in IgAN participants were possibly
associated with lower absorption of gastrointestinal pro-
teins, resulting in increased levels of faecal p-cresol
due to enhanced microbial proteolytic metabolism
and changes in the microbiota [39]. In a separately
published paper with the same cohort already in-
cluded in this review, Tao et al. [40] found that
when using an untargeted metabolomics approach,
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individuals with DN could be distinguished from age
and gender-matched diabetic controls by serum L-
arginine (AUC= 0.824) and taurine (AUC= 0.789) levels.
Nevertheless, greater employment of multi-omic tech-
nologies such as metabolomics needs to be integrated with
comprehensive data on the functional capability of the
microbiome and dietary intake in order to uncover some
of the most challenging questions concerning the preven-
tion and management of CKD and kidney disorders.
Modulation of the microbiome provides a new poten-
tial therapeutic target for preventing or personalising
treatment in kidney disease and disorders. Despite hy-
potheses that postulate deleterious effects of specific di-
ets and nutrients on the gastrointestinal microbiota
regarding uraemic toxin generation in kidney disease
[12, 26, 28, 78] and kidney stone formation [79], few ex-
plored this. Only three studies considered diet in their
study design [42, 50, 61], of which only two provided ad-
equate details of the dietary assessment methods used
and considered diet as co-variates in the analysis of the
microbiota. Further limitations within these studies
existed. For instance, Barrios et al. [61] noted that infor-
mation relating to dietary assessment and antibiotic use
was only available for 11% of their sample, making inter-
pretations of their results difficult. To date, the majority
of the published studies have focused mainly on the ef-
fect of nutritional supplements such as prebiotics and
probiotics to improve gut health and symptoms in indi-
viduals with CKD or kidney stones. Unfortunately, these
types of therapies add further to the pill burden for this
patient group [80] and have produced inconsistent re-
sults in either case [81–84]. Clinical trials that explore
the effects of dietary components, such as dietary fibre
in other clinical conditions are emerging [85]. Neverthe-
less, few studies have examined the effect of dietary pat-
terns on the gut microbiome in CKD or kidney stones.
Because nutrients are not consumed in isolation [86],
exploring the impact of whole foods and overall dietary
patterns on the gut microbiota may offer a superior and
rigorous methodological approach.
Further research into the lifestyle and environmental ex-
posures that differ across the spectrum of kidney disease
conditions, and whether certain factors individually have a
more significant impact, or whether there is a unifying ef-
fect on the microbiome, is essential to advance this area of
research. For instance, along with subsequent dietary re-
strictions, other drug therapies and the dialysis procedure
itself may explain variations observed between dialysis and
non-dialysis CKD, but also between adults receiving PD
compared to HD [1, 57]. For example, the clearance of
metabolic wastes that may influence the microbiome dif-
fers as HD therapy is discontinuous, while PD works con-
tinuously [1]. Maio et al. [45] noted that there were
significant differences in 58 bacterial taxa, seven of which
decreased over 12 weeks following the use of phosphate
binders (lanthanum carbonate). Hence, the impact of non-
antibiotic drugs unique to people with CKD requires fur-
ther exploration.
Our study has several limitations. Overall, the evalu-
ation of results relating to alterations in the gut micro-
biota was challenging to evaluate mainly due to
heterogeneity of the inclusion criteria of individuals re-
cruited, methodologies used and reporting of results. It
was thus not possible to conduct a meta-analysis. The
majority of cited studies had small sample sizes and
background information relating to the classification of
controls, diet, comorbidities, medications and other life-
style factors (such as smoking status, alcohol consump-
tion and physical activity) were poorly accounted for—
all of which may have influenced the results. The
strength of this review is reflected in its systematic ap-
proach to highlight the existing state of evidence in the
area of gut microbiota, kidney disease and kidney stone
disease. It serves to unify methods and study designs
needed to produce complementary findings and progress
in this field of research.
Conclusion
The gut microbiota profile of adults with kidney disease
and kidney stones was consistently reported to be sub-
stantially different from controls. Evidence for altered
genetic functions of the gut microbiota suggests a poten-
tial role of the gut microbiota in modulating host metab-
olism, particularly in the context of uraemic toxin
generation in adults with kidney disease—Although
greater investigation is still required. Studies with high
statistical power, comparable and reproducible methods
that include validated dietary assessment, as well as the
combined utilisation of more sophisticated multi-omic
technologies, are required to map functional capabilities
and more clearly elucidate the role of the microbiota in
kidney health.
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